专利文件修改标准新发展 评最高人民法院2011知行字第17号案  

Latest Developments in Patent Amendment Standards:Comments on Supreme People's Court's Case No.Zhixingzi 17/2011

作　　者：毛琎[1] 

机构地区：[1]国家知识产权局专利复审委员会行政诉讼处

出　　处：《中国专利与商标》2012年第2期60-71,共12页China Patents & Trademarks

摘　　要：最高人民法院于2011年提审了"氨氯地平、厄具沙坦复方制剂"发明专利行政纠纷案,以个案的方式对专利文件修改的适用标准作出指引。本文分析了判決涉及的专利文件修改的五个问题:如何从本领域技术人员的角度适用"直接地、毫无疑义地确定"标准、如何从立法本意角度考虑专利文件修改的限制、重新概括(二次慨括)是否会超范围、授权程序对确权程序中适用"修改超范围"的影响、无效程序中的修改方式的限定,通过对上述问题的分析阐述判决体现出来的专利文件修改标准的新发展。In 2011, the Supreme People＇s Court reviewed the administrative case involving the patent for invention of ＂amlodipine and irbesartan compound preparation＂, giving direction on the stan- dard for patent amendment in an individual case. This article probes into five issues of patent a- mendment involved in the court＇s decision： how to apply the direct and undoubted determina- tion standard from the perspective of a person skilled in the art; how to consider limitation on patent amendment in the light of legislative aim; whether re-generalisation （second generalisa- tion） goes beyond scope; how the patent right grant procedure impact the application of ＂going beyond scope＂ in the patent right affirmation procedure; and how to define ways of patent a- mendment. The latest developments in the patent amendment standards as embodied in the case are elaborated throuqh an analysis of all the issues.

关 键 词：最高人民法院 文件修改 发明专利 标准 氨氯地平 复方制剂 技术人员 纠纷案 

分 类 号：TP311[自动化与计算机技术—计算机软件与理论]